Browsing: A Phase 2/3 trial conducted by Pfizer and BioNTech revealed that the Covid-19 vaccine was safe and generated a “robust antibody response” in children ages 5 to 11.

These are the first such results released for this age group for a US Covid-19 vaccine. Pfizer said it plans to submit to the U.S. Food and Drug Administration for emergency use authorization soon.